ANDA 209408, held by Samson Medcl. Cefepime Hydrochloride.
As of Nov 16, 2026, ANDA 209408 (Cefepime Hydrochloride In Plastic Container), held by Samson Medcl, was first approved by FDA on Aug 21, 2018, with 0 approved supplements and 0 published complete response letters.
Cefepime for Injection, USP is a cephalosporin antibacterial indicated for the treatment of the following infections caused by susceptible strains of the designated microorganisms: Pneumonia. Empiric therapy for febrile neutropenic patients. Uncomplicated and complicated urinary tract infections (including pyelonephritis). Uncomplicated skin and skin structure infections. Complicated intra-abdominal infections (used in combination with metronidazole) in adults.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 21, 2018 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Cefepime Hydrochloride In Plastic ContainerEQ 100GM BASE · powder;intravenous | Cefepime Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters